Autoinjectors are medical devices designed to deliver a single dose of a particular (typically life-saving) drug through the spring-loaded syringes. By design, autoinjectors are easy to use and are intended for self-administration by patients, or administration by untrained personnel. Autoinjectors are used to deliver single doses of drugs to patients and are characterized as springloaded syringes, designed for self-administration by patients or untrained personnel, especially during emergency situations.
The global autoinjectors market report provides market size estimates (Revenue USD million – 2014 to 2021) for key market segments based on product type (prefilled, reusable, standardized, and customized), its applications (anaphylaxis, multiple sclerosis and rheumatoid arthritis), and forecasts growth trends (CAGR% – 2017 to 2021).
The global autoinjectors market segmentation is based on geography (regional and country based). The global autoinjectors market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products,
technologies and services offered, and recent developments. The global autoinjectors market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global autoinjectors market and included in this report are Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Mylan, Inc., Novartis International AG, Pfizer, Inc., Sanofi, Scandinavian Health Limited (SHL) Group, Unilife Corporation, and Ypsomed Holdings AG.